期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

2017年上半年美国FDA批准的新分子实体与评价:神经系统疾病和皮肤病治疗用药

Updates of New Molecular Entities Approved by the FDA in the First-Half of 2017: Drugs for Neurological Diseases and Skin Disorders
下载PDF
导出
摘要 2017年上半年,FDA共批准了23个新分子实体和新生物制品,其中新分子实体16种,新生物制品7种。神经系统、肿瘤和皮肤病治疗药物获批数量位居前三位。本系列文章将对这些新药进行介绍和评价,本文介绍神经系统疾病和皮肤病新药。 The US FDA approved 23 new molecular entities and new therapeutic biological products in the first-half of 2017. This article provides anupdate and evaluation of the new drugs approved for the treatment of neurological diseases and skin disorders.
作者 孙树森 赵志刚 SUN Shu-sen;ZHAO Zhi-gang(College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01119, United States;Department of Pharmacy,Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, China)
机构地区 美国西新英格兰大学药学与健康科学学院 首都医科大学附属北京天坛医院药学部
出处 《药品评价》 CAS 2017年第24期11-18,共8页 Drug Evaluation
关键词 FDA 2017年上半年 新分子实体 神经系统 皮肤病 FDA First Half of 2017 New Molecular Entity Neurology Skin
分类号 R971 [医药卫生—药品]
  • 相关文献

二级参考文献22

  • 1PeytonL, Greene J. Irritable bowel syndrome: current and emerging treatment options[J]. PT, 2014, 39(8): 567-578.
  • 2Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review[J]. JAMA, 2015, 313(9): 949-958.
  • 3Paul C, Lacour J-P, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial(JUNCTURE)[J]. J EurAcad Dermatol VenereoL 2015, 29(6): 1082-1090.
  • 4Blaivelt A, Pfinz JC, Gottlieb AB, et al. Secukinumab administration by pm-fiUed syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis(FEATURE)[J]. Br J Dermatol, 2015, 172(2): 484-493.
  • 5Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results ot'cwo phase 3 trials[J]. N Engl J Med, 2014, 371(4): 326-338.
  • 6Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial[J]. J Am Acad Dermatol, 2015, 2015 Jun 16. pii: S0190-9622(15)01683-7. doi: 10. 1016/j. jaad. 2015.05.013. [Epub ahead of print].
  • 7脱氧胆酸药品说明书[OL].Kybella website.http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/2063330riglsOOOlbl.pdf.2015-4-29/2015.6.25.
  • 8Vazquez JA, Gonzalez Patzan LD, Stricklin D, et al. Efficacy and safety of ceiazidime-avibactamversus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study[J]. Curt Med Res Opin, 2012, 28(12): 1921-1931.
  • 9Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated inWa-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial[J]. J AnfimicrobChemother, 2013, 68(5): 1182-1192.
  • 10Me Cormack PL. Isavuconazonium: first global approval[J]. Drugs, 2015, 75: 817-822.

共引文献14

药品评价
2017年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部